| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,824 | 1,860 | 20.05. | |
| 1,844 | 1,860 | 20.05. |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Genovis AB: Communiqué from Genovis AB (publ) Annual General Meeting May 18, 2026 | 55 | GlobeNewswire (Europe) | The Annual General Meeting adopted the following resolutions:
The Balance Sheet and Income Statement as well as the Consolidated Income Statement and the Consolidated Balance Sheet were adopted.The... ► Artikel lesen | |
| 12.05. | Genovis AB: Genovis Announces Change in Chief Financial Officer Position | 135 | GlobeNewswire (Europe) | Genovis AB announces that Chief Financial Officer (CFO) Magnus Långberg has decided to leave the company to pursue a new opportunity outside the Group. Magnus Långberg will remain in his current role... ► Artikel lesen | |
| 11.05. | Genovis AB: Genovis and MGI Tech Strengthen Collaboration to Advance RNA Sequencing Solutions | 154 | GlobeNewswire (Europe) | Genovis AB and MGI Tech Co., Ltd. today announce a strengthened collaboration to advance RNA sequencing solutions. The companies have expanded their commercial agreement to integrate Genovis' SEQURNA... ► Artikel lesen | |
| 28.04. | Genovis AB Reveals Increase In Q1 Income | 3 | RTTNews | ||
| 28.04. | Genovis AB: Genovis AB Interim Report January-March 2026 | 89 | GlobeNewswire (Europe) | Stable growth, new products, and expanded business opportunities
January - March 2026Net sales totaled SEK 33,506 (32,292) thousand, representing a growth of 4%, corresponding to 17% when adjusted for... ► Artikel lesen | |
| 31.03. | Genovis AB: Genovis and Plasmidsaurus Introduce SEQguard Dino Preserve - Enabling Ambient-Temperature RNA Shipping for Next-Generation Sequencing | 169 | GlobeNewswire (Europe) | Genovis AB today announces the commercial launch of SEQguard Dino Preserve, an RNA preservation product tested and optimized for Plasmidsaurus, a leading Sequencing as a Service company. The product... ► Artikel lesen | |
| 25.03. | Genovis AB: Genovis Enters Non-Exclusive License Agreement for EndoS2 Enzyme Technology for Antibody-Drug Conjugate (ADC) Development and Commercialization | 213 | GlobeNewswire (Europe) | Genovis AB announces that it has entered into a non-exclusive, worldwide license agreement with a US-based private biotech company, granting rights to use Genovis' proprietary EndoS2 enzyme technology... ► Artikel lesen | |
| GENOVIS Aktie jetzt für 0€ handeln | |||||
| 19.03. | Genovis AB: Genovis and Single Cell Discoveries Enter Strategic Partnership for Large-Scale Transcriptomics Analyses | 378 | GlobeNewswire (Europe) | Genovis AB, a leading provider of innovative enzyme technologies, today announces a strategic partnership with Single Cell Discoveries to broaden the application of the SEQURNA® Thermostable RNase Inhibitor... ► Artikel lesen | |
| 12.02. | Genovis AB Q4 Income Advances | 1 | RTTNews | ||
| 12.02. | Genovis AB: Genovis AB Year-end Report January-December 2025 | 148 | GlobeNewswire (Europe) | Strong finish to the year - recovery in customer activity in the fourth quarter
October - December 2025Net sales totaled SEK 40,252 (27,936) thousand, representing a growth of 44%, corresponding to... ► Artikel lesen | |
| 07.11.25 | Genovis AB: Genovis AB Interim report January-September 2025 | 199 | GlobeNewswire (Europe) | Shift in Growth Timing in a Volatile Market - Strong Start to the Fourth Quarter
July - September 2025Genovis AB acquired the remaining 75% of Sequrna AB on July 1, 2025, by exercising the purchase... ► Artikel lesen | |
| 17.10.25 | Genovis AB: Genovis receives order worth approximately 1 million euros from global pharmaceutical company | 213 | GlobeNewswire (Europe) | Genovis AB, a leading provider of innovative enzyme technologies, today announced it has received an order with a total value of approximately EUR 1 million (SEK 11 million) from a global pharmaceutical... ► Artikel lesen | |
| 12.08.25 | Genovis AB: Genovis AB Half-Yearly report January - June 2025 | 308 | GlobeNewswire (Europe) | Strong organic growth and doubled operating profit in the enzyme business
April - June 2025Net sales totaled SEK 28,871 (24,601)* thousand, with a growth rate of 17 %, 28 % when adjusted for currency... ► Artikel lesen | |
| 24.07.25 | Thermo Fisher, Genovis Expand License Agreement For Therapeutic Antibody-Drug Conjugate Development | 762 | AFX News | STOCKHOLM (dpa-AFX) - Sweden-headquartered Genovis AB (GENO.ST), a provider of innovative enzyme technologies, on Thursday announced an expansion of its license agreement with U.S.-based Thermo... ► Artikel lesen | |
| 21.05.25 | Genovis AB: Genovis AB Interim report January - March 2025 | 257 | GlobeNewswire (Europe) | Record quarter for the enzyme business within Analytics - strong operating profit despite currency effects.
January - March 2025Net sales totaled SEK 32,292 (25,808)* thousand, with a growth rate of... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 77,75 | +1,63 % | Ihre wichtigsten Termine: Alle Blicke auf: Fraport, Biontech, Nagarro, Freenet & Intercontinental Exchange | © Foto: UnsplashGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 07:00 Uhr, Deutschland:... ► Artikel lesen | |
| EVOTEC | 4,900 | +3,38 % | Evotec-Aktie mit -11% Einbruch - Panik nimmt weiter zu | Die Evotec-Aktie ist gestern -10,63% eingebrochen und geriet damit erneut massiv unter Druck. Nach einer zuvor kurzfristigen Stabilisierung verschlechterte sich das Chartbild wieder, während wichtige... ► Artikel lesen | |
| BB BIOTECH | 48,000 | +0,10 % | Aktien KW 17 Märkte im Würgegriff. Planloser Trump , selbstbewusterer Iran. Lösungen müssen her. News. Rheinmetall. ITM Power. Porsche. The Platform Group. K+S. Bugatti. Circus. Surteco. NanoRepro. BB Biotech. Mensch und Maschine. ATOSS. MHP Hotel | Aktien - letzte Woche warteten die Märkte auf eine Lösung des Iran-Kriegs. Aber die Iraner sehen sich im Vorteil und Trump verlängert "auf unbestimmte Zeit" den Waffenstillstand. Aber die Strasse von... ► Artikel lesen | |
| MEDIGENE | 0,026 | -16,03 % | PTA-Adhoc: Medigene AG: Widerruf der Zulassung der Aktien der Medigene AG zum Handel im regulierten Markt | DJ PTA-Adhoc: Medigene AG: Widerruf der Zulassung der Aktien der Medigene AG zum Handel im regulierten Markt
Veröffentlichung von Insiderinformationen gemäß Artikel 17 MAR Schlagwort(e): Sonstiges... ► Artikel lesen | |
| QIAGEN | 29,910 | +0,66 % | QIAGEN N.V.: QIAGEN to advance AI-driven drug discovery with graph-based AI and curated bioinformatics knowledge with NVIDIA | Collaboration integrates NVIDIA accelerated computing and the NVIDIA BioNeMo platform with QIAGEN Digital Insights' curated biomedical knowledge bases Goal to advance how disease mechanisms... ► Artikel lesen | |
| MODERNA | 41,380 | -0,02 % | Roivant anticipates $950M Moderna payment in July as it outlines 2H 2026 mosliciguat and IMVT-1402 readouts | ||
| PAION | 0,072 | -25,52 % | XFRA MISTRADE ANTRAG IN ISIN DE000A3E5EG5 WURDE STATTGEGEBEN | Dem Mistrade-Antrag wurde stattgegeben. Folgende Geschaefte in der ISIN DE000A3E5EG5, Wertpapier-Name: PAION AG INH O.N., wurden aufgehoben:ISIN Datum Zeit Volumen PreisDE000A3E5EG5 02.02.2026 08:13:40 300 0... ► Artikel lesen | |
| VALNEVA | 2,476 | -0,80 % | Aktien im Fokus - Deutsche Telekom: Jetzt oder nie - DEFAMA, Evotec, SFC Energy, Valneva und Verbio | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| AMGEN | 286,85 | +0,58 % | Dividendenbekanntmachungen (15.05.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) A10 NETWORKS INC US0021211018 0,06 USD 0,0514 EUR AF GRUPPEN ASA NO0003078107 6,5 NOK 0,6029 EUR AGCO CORPORATION US0010841023 0... ► Artikel lesen | |
| EPIGENOMICS | 0,930 | -0,53 % | PTA-HV: Epigenomics AG: Einladung zur ordentlichen Hauptversammlung | DJ PTA-HV: Epigenomics AG: Einladung zur ordentlichen Hauptversammlung
Hauptversammlung gemäß -- 121 Abs. 4a AktG
Epigenomics AG: Einladung zur ordentlichen Hauptversammlung
Heidelberg... ► Artikel lesen | |
| NOVAVAX | 7,970 | 0,00 % | Novavax, Inc.: Novavax Reports First Quarter 2026 Financial Results and Operational Highlights | Total revenue of $140 million in the first quarter of 2026
Pfizer agreement announced in January for non-exclusive license to utilize Matrix-M® in two infectious... ► Artikel lesen | |
| STRYKER | 273,60 | +0,44 % | Stryker Buys Amplitude Vascular Systems For Upto $835 Mln To Expand Vascular Treatment Business | WASHINGTON (dpa-AFX) - Tuesday, BioStar Capital announced that Amplitude Vascular Systems, Inc., a medical technology company, has been acquired by Stryker Corporation (SYK) at a purchase price... ► Artikel lesen | |
| BIOGEN | 161,94 | +0,22 % | Biogen Inc.: Biogen Completes Acquisition of Apellis Pharmaceuticals | CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the successful completion of the acquisition of Apellis Pharmaceuticals, Inc. (Nasdaq: APLS). Apellis... ► Artikel lesen | |
| BIOFRONTERA | 2,470 | +1,65 % | Biofrontera stock rating cut to Speculative Buy by Benchmark | ||
| HEIDELBERG PHARMA | 2,780 | +1,83 % | EQS-HV: Heidelberg Pharma AG: Bekanntmachung der Einberufung zur Hauptversammlung am 23.06.2026 in Ladenburg mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG | EQS-News: Heidelberg Pharma AG
/ Bekanntmachung der Einberufung zur Hauptversammlung
Heidelberg Pharma AG: Bekanntmachung der Einberufung zur Hauptversammlung am 23.06.2026 in... ► Artikel lesen |